Optilume™ BPH Catheter System in Men With Symptomatic BPH

NAActive, not recruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

August 23, 2022

Study Completion Date

May 31, 2027

Conditions
Benign Prostatic Hyperplasia
Interventions
DEVICE

Optilume BPH Catheter System

The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.

DEVICE

Optilume Sham Device

21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)

Trial Locations (21)

10016

Manhattan Medical Research Practice, PLLC, New York

10065

Weill Cornell Medical College, New York

11530

AccuMed Research Associates, Garden City

21076

Chesapeake Urology Research Associates, Hanover

21204

Chesapeake Urology Research Associates, Towson

27612

Associated Urologists of NC, Raleigh

29572

Carolina Urologic Research Center, Myrtle Beach

32114

Advanced Urology Institute, Daytona Beach

33615

Florida Urology Partners, Tampa

60010

Comprehensive Urologic Care, Lake Barrington

71106

Regional Urology, LLC, Shreveport

72211

Arkansas Urology, Little Rock

77598

Clear Lake Specialties, Webster

78745

Urology Austin, PLLC, Austin

78750

North Austin Urology, Austin

79912

Rio Grande Urology, El Paso

80401

Colorado Clinical Research, Golden

89144

Sheldon Freedman MD, Ltd, Las Vegas

07631

New Jersey Urology, Englewood

M5G 1E2

University Urology Associates, Toronto

H2X 3E4

University of Montreal Hospital Center (CHUM), Montreal

All Listed Sponsors
collaborator

ClinLogix. LLC

INDUSTRY

lead

Urotronic Inc.

INDUSTRY